Scinai Immunotherapeutics Return on Equity

Scinai Immunotherapeutics (SCNI) currently reports a ROE of -27.13%. That is below the Healthcare sector average of 29.33%. Use the charts on this page to explore Scinai Immunotherapeutics's ROE history and peer comparisons.

Scinai Immunotherapeutics's ROE of -27.13% is lower than the Healthcare sector average of 29.33%. That is roughly 192.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Scinai Immunotherapeutics's current -27.13% should be judged against Healthcare norms (sector average: 29.33%) and against SCNI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -27.13%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.33%. From there, open related valuation or income-statement pages for Scinai Immunotherapeutics, and consider following SCNI for alerts when major investors trade the stock.

Scinai Immunotherapeutics is classified in the Healthcare sector. On ROE, it currently shows -27.13% versus a sector average near 29.33%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SCNI with unrelated industries.